Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-02

AUTHORS

Adil Daud, Harriet M Kluger, Razelle Kurzrock, Frauke Schimmoller, Aaron L Weitzman, Thomas A Samuel, Ali H Moussa, Michael S Gordon, Geoffrey I Shapiro

ABSTRACT

BACKGROUND: A phase II randomised discontinuation trial assessed cabozantinib (XL184), an orally bioavailable inhibitor of tyrosine kinases including VEGF receptors, MET, and AXL, in a cohort of patients with metastatic melanoma. METHODS: Patients received cabozantinib 100 mg daily during a 12-week lead-in. Patients with stable disease (SD) per Response Evaluation Criteria in Solid Tumours (RECIST) at week 12 were randomised to cabozantinib or placebo. Primary endpoints were objective response rate (ORR) at week 12 and postrandomisation progression-free survival (PFS). RESULTS: Seventy-seven patients were enroled (62% cutaneous, 30% uveal, and 8% mucosal). At week 12, the ORR was 5%; 39% of patients had SD. During the lead-in phase, reduction in target lesions from baseline was seen in 55% of evaluable patients overall and in 59% of evaluable patients with uveal melanoma. Median PFS after randomisation was 4.1 months with cabozantinib and 2.8 months with placebo (hazard ratio of 0.59; P=0.284). Median PFS from study day 1 was 3.8 months, 6-month PFS was 33%, and median overall survival was 9.4 months. The most common grade 3/4 adverse events were fatigue (14%), hypertension (10%), and abdominal pain (8%). One treatment-related death was reported from peritonitis due to diverticular perforation. CONCLUSIONS: Cabozantinib has clinical activity in patients with metastatic melanoma, including uveal melanoma. Further clinical investigation is warranted. More... »

PAGES

432

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/bjc.2016.419

DOI

http://dx.doi.org/10.1038/bjc.2016.419

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1048567126

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28103611


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anilides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Belgium", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Israel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-met", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Vascular Endothelial Growth Factor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Skin Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Uveal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Withholding Treatment", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of California, San Francisco", 
          "id": "https://www.grid.ac/institutes/grid.266102.1", 
          "name": [
            "University of California, San Francisco Medical Center at Parnassus, 1600 Divisadero Street, MZ Bldg A, San Francisco, CA 94115, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Daud", 
        "givenName": "Adil", 
        "id": "sg:person.01106713311.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106713311.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yale University", 
          "id": "https://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, PO Box 208028, New Haven, CT 06520-8028, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kluger", 
        "givenName": "Harriet M", 
        "id": "sg:person.01336750727.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336750727.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "University of California, San Diego Moores Cancer Center, 3855 Health Sciences Drive, MC #0658, La Jolla, CA 92093-0658, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kurzrock", 
        "givenName": "Razelle", 
        "id": "sg:person.0772022470.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772022470.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Exelixis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.428377.d", 
          "name": [
            "Exelixis Inc., 210 E. Grand Avenue, South San Francisco, CA 94080, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schimmoller", 
        "givenName": "Frauke", 
        "id": "sg:person.01150411250.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150411250.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Exelixis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.428377.d", 
          "name": [
            "Exelixis Inc., 210 E. Grand Avenue, South San Francisco, CA 94080, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Weitzman", 
        "givenName": "Aaron L", 
        "id": "sg:person.01173210730.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173210730.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cleveland Clinic Florida", 
          "id": "https://www.grid.ac/institutes/grid.418628.1", 
          "name": [
            "Department of Hematology/Oncology, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Samuel", 
        "givenName": "Thomas A", 
        "id": "sg:person.01143554436.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01143554436.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Cancer Care Associates, 1810 E 15th Street, Tulsa, OK 74104, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moussa", 
        "givenName": "Ali H", 
        "id": "sg:person.016216430013.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016216430013.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pinnacle Oncology Hematology", 
          "id": "https://www.grid.ac/institutes/grid.492843.0", 
          "name": [
            "Pinnacle Oncology Hematology, 9055 E. Del Camino, Suite 100, Scottsdale, AZ 85258, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gordon", 
        "givenName": "Michael S", 
        "id": "sg:person.0713550751.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0713550751.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dana\u2013Farber Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.65499.37", 
          "name": [
            "Department of Medical Oncology, Dana-Farber Cancer Institute, Early Drug Development Center, 450 Brookline Avenue, Boston, MA 02215, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shapiro", 
        "givenName": "Geoffrey I", 
        "id": "sg:person.0752005421.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752005421.01"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1056/nejmoa1408868", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000859328"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/jid.2011.421", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002802838", 
          "https://doi.org/10.1038/jid.2011.421"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2009.02.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002939839"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.cmr.0000222598.27438.82", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003133820"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.cmr.0000222598.27438.82", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003133820"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(12)60868-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003772891"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0010770", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004687723"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmra041245", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005930121"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.03.6723", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007324791"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0895-4356(93)90163-u", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008750072"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ppo.0b013e3181bd0431", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009285554"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ppo.0b013e3181bd0431", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009285554"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ppo.0b013e3181bd0431", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009285554"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1412082", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012352031"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2009.01.021", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012366197"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(14)60958-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012632588"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2014.6096", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012801179"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-10-0489", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012978908"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.45.0494", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013364059"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1593/neo.111102", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017478734"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/2159-8290.cd-11-0240", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021811835"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature00766", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023536940", 
          "https://doi.org/10.1038/nature00766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature00766", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023536940", 
          "https://doi.org/10.1038/nature00766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12094-011-0719-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023891155", 
          "https://doi.org/10.1007/s12094-011-0719-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ctrv.2012.01.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024044063"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1504030", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024843336"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ncomms6712", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025893090", 
          "https://doi.org/10.1038/ncomms6712"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-11-0264", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025899139"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-03-0245", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026966842"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clindermatol.2012.08.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027903625"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cmr.0000000000000242", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027998728"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cmr.0000000000000242", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027998728"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1000584", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028808360"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-06-0776", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028934066"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.32.4145", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031276220"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-10-3169", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031380951"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032301848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.12.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037621530"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.canlet.2012.01.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039022477"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1103782", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041864150"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6600919", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041973162", 
          "https://doi.org/10.1038/sj.bjc.6600919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6600919", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041973162", 
          "https://doi.org/10.1038/sj.bjc.6600919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1406037", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047704810"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc3205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048356671", 
          "https://doi.org/10.1038/nrc3205"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature10144", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050798018", 
          "https://doi.org/10.1038/nature10144"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1112302", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051449373"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/j.1552-4604.1975.tb05919.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052076247"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1003466", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052212829"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/jid.2011.218", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052787397", 
          "https://doi.org/10.1038/jid.2011.218"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature11183", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053677952", 
          "https://doi.org/10.1038/nature11183"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1538-7445.am2011-3587", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063238417"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.21037/atm.2016.05.04", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1068831922"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076575043", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078586743", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.29.15_suppl.3010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083947519"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.34.15_suppl.9502", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106842822"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.34.15_suppl.9530", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106842850"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-02", 
    "datePublishedReg": "2017-02-01", 
    "description": "BACKGROUND: A phase II randomised discontinuation trial assessed cabozantinib (XL184), an orally bioavailable inhibitor of tyrosine kinases including VEGF receptors, MET, and AXL, in a cohort of patients with metastatic melanoma.\nMETHODS: Patients received cabozantinib 100\u2009mg daily during a 12-week lead-in. Patients with stable disease (SD) per Response Evaluation Criteria in Solid Tumours (RECIST) at week 12 were randomised to cabozantinib or placebo. Primary endpoints were objective response rate (ORR) at week 12 and postrandomisation progression-free survival (PFS).\nRESULTS: Seventy-seven patients were enroled (62% cutaneous, 30% uveal, and 8% mucosal). At week 12, the ORR was 5%; 39% of patients had SD. During the lead-in phase, reduction in target lesions from baseline was seen in 55% of evaluable patients overall and in 59% of evaluable patients with uveal melanoma. Median PFS after randomisation was 4.1 months with cabozantinib and 2.8 months with placebo (hazard ratio of 0.59; P=0.284). Median PFS from study day 1 was 3.8 months, 6-month PFS was 33%, and median overall survival was 9.4 months. The most common grade 3/4 adverse events were fatigue (14%), hypertension (10%), and abdominal pain (8%). One treatment-related death was reported from peritonitis due to diverticular perforation.\nCONCLUSIONS: Cabozantinib has clinical activity in patients with metastatic melanoma, including uveal melanoma. Further clinical investigation is warranted.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/bjc.2016.419", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "116"
      }
    ], 
    "name": "Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma", 
    "pagination": "432", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "e75db77b0af4e63d8838ea2ff6974a088f9a6c68a35257b7e9bcbfb314090f77"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28103611"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0370635"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/bjc.2016.419"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1048567126"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/bjc.2016.419", 
      "https://app.dimensions.ai/details/publication/pub.1048567126"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T20:53", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8684_00000551.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/bjc2016419"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bjc.2016.419'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bjc.2016.419'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bjc.2016.419'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bjc.2016.419'


 

This table displays all metadata directly associated to this object as RDF triples.

388 TRIPLES      21 PREDICATES      101 URIs      42 LITERALS      30 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/bjc.2016.419 schema:about N00f59e6bb01142b1b96b33adee14a421
2 N04ac60a3f1a34a388c0a71cd5068e89a
3 N0ec916243492407a803c37245e231935
4 N3078de8d7f0b45e08efa045e08a59fbd
5 N37830e2bda6d44cf8f7e41b255646d75
6 N38135e13940a4fc9bee00a8366994465
7 N44ac3c50bee941f0a931d25db7176a09
8 N450b55436d5b4042bb6c746f840da844
9 N4e3013f2c1014221b8100fe4b0e9b8d7
10 N51746248dad540e6806005cc77a98ecd
11 N5f9c4b64145e40f9b9b8df0db161d59b
12 N6dc8f01b82f64d7d897d4f5a45cf383e
13 N76097c5c632443f4bcf6e830ae682a71
14 N7aacca533d5b4a2e8f70ad89b52db5b0
15 N85b0c8b0a9af4e98b5915a94117cbf95
16 N9294eefcafc54106af639d876ed34e73
17 N93e18c697bd84458971342dd3641cc72
18 Nc4452d54077440db93719a1bc5267faf
19 Nca3b4351e49247c595de44968dc50fab
20 Ncdc5a838457e42c0a68c52d457787555
21 Nfffe2b0ef15d43208d2d960a01a7d460
22 anzsrc-for:11
23 anzsrc-for:1112
24 schema:author Nd04c1d87be1f4fb9ab91d8b66486f086
25 schema:citation sg:pub.10.1007/s12094-011-0719-5
26 sg:pub.10.1038/jid.2011.218
27 sg:pub.10.1038/jid.2011.421
28 sg:pub.10.1038/nature00766
29 sg:pub.10.1038/nature10144
30 sg:pub.10.1038/nature11183
31 sg:pub.10.1038/ncomms6712
32 sg:pub.10.1038/nrc3205
33 sg:pub.10.1038/sj.bjc.6600919
34 https://app.dimensions.ai/details/publication/pub.1076575043
35 https://app.dimensions.ai/details/publication/pub.1078586743
36 https://doi.org/10.1001/jama.2014.6096
37 https://doi.org/10.1002/j.1552-4604.1975.tb05919.x
38 https://doi.org/10.1016/0895-4356(93)90163-u
39 https://doi.org/10.1016/j.canlet.2012.01.026
40 https://doi.org/10.1016/j.ccr.2009.01.021
41 https://doi.org/10.1016/j.ccr.2009.02.007
42 https://doi.org/10.1016/j.clindermatol.2012.08.013
43 https://doi.org/10.1016/j.ctrv.2012.01.002
44 https://doi.org/10.1016/j.ejca.2008.12.015
45 https://doi.org/10.1016/s0140-6736(12)60868-x
46 https://doi.org/10.1016/s0140-6736(14)60958-2
47 https://doi.org/10.1056/nejmoa1000584
48 https://doi.org/10.1056/nejmoa1003466
49 https://doi.org/10.1056/nejmoa1103782
50 https://doi.org/10.1056/nejmoa1112302
51 https://doi.org/10.1056/nejmoa1406037
52 https://doi.org/10.1056/nejmoa1408868
53 https://doi.org/10.1056/nejmoa1412082
54 https://doi.org/10.1056/nejmoa1504030
55 https://doi.org/10.1056/nejmra041245
56 https://doi.org/10.1093/jnci/92.3.205
57 https://doi.org/10.1097/01.cmr.0000222598.27438.82
58 https://doi.org/10.1097/cmr.0000000000000242
59 https://doi.org/10.1097/ppo.0b013e3181bd0431
60 https://doi.org/10.1158/0008-5472.can-03-0245
61 https://doi.org/10.1158/0008-5472.can-10-0489
62 https://doi.org/10.1158/1078-0432.ccr-06-0776
63 https://doi.org/10.1158/1078-0432.ccr-10-3169
64 https://doi.org/10.1158/1535-7163.mct-11-0264
65 https://doi.org/10.1158/1538-7445.am2011-3587
66 https://doi.org/10.1158/2159-8290.cd-11-0240
67 https://doi.org/10.1200/jco.2005.03.6723
68 https://doi.org/10.1200/jco.2010.32.4145
69 https://doi.org/10.1200/jco.2011.29.15_suppl.3010
70 https://doi.org/10.1200/jco.2012.45.0494
71 https://doi.org/10.1200/jco.2016.34.15_suppl.9502
72 https://doi.org/10.1200/jco.2016.34.15_suppl.9530
73 https://doi.org/10.1371/journal.pone.0010770
74 https://doi.org/10.1593/neo.111102
75 https://doi.org/10.21037/atm.2016.05.04
76 schema:datePublished 2017-02
77 schema:datePublishedReg 2017-02-01
78 schema:description BACKGROUND: A phase II randomised discontinuation trial assessed cabozantinib (XL184), an orally bioavailable inhibitor of tyrosine kinases including VEGF receptors, MET, and AXL, in a cohort of patients with metastatic melanoma. METHODS: Patients received cabozantinib 100 mg daily during a 12-week lead-in. Patients with stable disease (SD) per Response Evaluation Criteria in Solid Tumours (RECIST) at week 12 were randomised to cabozantinib or placebo. Primary endpoints were objective response rate (ORR) at week 12 and postrandomisation progression-free survival (PFS). RESULTS: Seventy-seven patients were enroled (62% cutaneous, 30% uveal, and 8% mucosal). At week 12, the ORR was 5%; 39% of patients had SD. During the lead-in phase, reduction in target lesions from baseline was seen in 55% of evaluable patients overall and in 59% of evaluable patients with uveal melanoma. Median PFS after randomisation was 4.1 months with cabozantinib and 2.8 months with placebo (hazard ratio of 0.59; P=0.284). Median PFS from study day 1 was 3.8 months, 6-month PFS was 33%, and median overall survival was 9.4 months. The most common grade 3/4 adverse events were fatigue (14%), hypertension (10%), and abdominal pain (8%). One treatment-related death was reported from peritonitis due to diverticular perforation. CONCLUSIONS: Cabozantinib has clinical activity in patients with metastatic melanoma, including uveal melanoma. Further clinical investigation is warranted.
79 schema:genre research_article
80 schema:inLanguage en
81 schema:isAccessibleForFree true
82 schema:isPartOf N89d14967743247f7a067b7be404ada26
83 Ne67d074a93f0487e81eeaeb6e773a0ae
84 sg:journal.1017082
85 schema:name Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
86 schema:pagination 432
87 schema:productId N1a6566e647f34910a9a52e748e6c8c48
88 N404fc57cf0e249d080c6f0c64bfb7fa0
89 N44d1589d6ac2470fb07040b9d1a5b7b7
90 N85be8459486641df9037850f991186c8
91 Ne4a05816d7204435b45a98581181ccbe
92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048567126
93 https://doi.org/10.1038/bjc.2016.419
94 schema:sdDatePublished 2019-04-10T20:53
95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
96 schema:sdPublisher N5ea702e4cea84af59ffb291b2ee10cf0
97 schema:url https://www.nature.com/articles/bjc2016419
98 sgo:license sg:explorer/license/
99 sgo:sdDataset articles
100 rdf:type schema:ScholarlyArticle
101 N00f59e6bb01142b1b96b33adee14a421 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Belgium
103 rdf:type schema:DefinedTerm
104 N04ac60a3f1a34a388c0a71cd5068e89a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Neoplasm Metastasis
106 rdf:type schema:DefinedTerm
107 N0c3b3ba0bb4b481babbbadea2152cb33 schema:name Cancer Care Associates, 1810 E 15th Street, Tulsa, OK 74104, USA
108 rdf:type schema:Organization
109 N0eb571bbb0764e0c8eaf832c57a686f1 rdf:first sg:person.0713550751.04
110 rdf:rest N6b56922aba7b41c4b50c44f97dc2e6aa
111 N0ec916243492407a803c37245e231935 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Withholding Treatment
113 rdf:type schema:DefinedTerm
114 N139689086bba436e95302a693c5766c1 rdf:first sg:person.01336750727.45
115 rdf:rest N606e2c3936104b98b2399d94ea0fbfdb
116 N1a6566e647f34910a9a52e748e6c8c48 schema:name readcube_id
117 schema:value e75db77b0af4e63d8838ea2ff6974a088f9a6c68a35257b7e9bcbfb314090f77
118 rdf:type schema:PropertyValue
119 N2f0ce00aa49f452fb9ea9f55dc667146 rdf:first sg:person.016216430013.43
120 rdf:rest N0eb571bbb0764e0c8eaf832c57a686f1
121 N3078de8d7f0b45e08efa045e08a59fbd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name United States
123 rdf:type schema:DefinedTerm
124 N37830e2bda6d44cf8f7e41b255646d75 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Adult
126 rdf:type schema:DefinedTerm
127 N38135e13940a4fc9bee00a8366994465 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Aged, 80 and over
129 rdf:type schema:DefinedTerm
130 N404fc57cf0e249d080c6f0c64bfb7fa0 schema:name dimensions_id
131 schema:value pub.1048567126
132 rdf:type schema:PropertyValue
133 N44ac3c50bee941f0a931d25db7176a09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Middle Aged
135 rdf:type schema:DefinedTerm
136 N44d1589d6ac2470fb07040b9d1a5b7b7 schema:name nlm_unique_id
137 schema:value 0370635
138 rdf:type schema:PropertyValue
139 N450b55436d5b4042bb6c746f840da844 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Humans
141 rdf:type schema:DefinedTerm
142 N46afef03e163443bb0873b9f2258ff01 rdf:first sg:person.01173210730.54
143 rdf:rest N780f520411d948168cfe7daa91d367dd
144 N4e3013f2c1014221b8100fe4b0e9b8d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Female
146 rdf:type schema:DefinedTerm
147 N51746248dad540e6806005cc77a98ecd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Male
149 rdf:type schema:DefinedTerm
150 N5ea702e4cea84af59ffb291b2ee10cf0 schema:name Springer Nature - SN SciGraph project
151 rdf:type schema:Organization
152 N5f9c4b64145e40f9b9b8df0db161d59b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Receptors, Vascular Endothelial Growth Factor
154 rdf:type schema:DefinedTerm
155 N606e2c3936104b98b2399d94ea0fbfdb rdf:first sg:person.0772022470.64
156 rdf:rest N7015758e66954a7ab24a5be4e364a5ab
157 N6b56922aba7b41c4b50c44f97dc2e6aa rdf:first sg:person.0752005421.01
158 rdf:rest rdf:nil
159 N6dc8f01b82f64d7d897d4f5a45cf383e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Skin Neoplasms
161 rdf:type schema:DefinedTerm
162 N7015758e66954a7ab24a5be4e364a5ab rdf:first sg:person.01150411250.57
163 rdf:rest N46afef03e163443bb0873b9f2258ff01
164 N76097c5c632443f4bcf6e830ae682a71 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Survival Analysis
166 rdf:type schema:DefinedTerm
167 N780f520411d948168cfe7daa91d367dd rdf:first sg:person.01143554436.02
168 rdf:rest N2f0ce00aa49f452fb9ea9f55dc667146
169 N7aacca533d5b4a2e8f70ad89b52db5b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Israel
171 rdf:type schema:DefinedTerm
172 N85b0c8b0a9af4e98b5915a94117cbf95 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Uveal Neoplasms
174 rdf:type schema:DefinedTerm
175 N85be8459486641df9037850f991186c8 schema:name doi
176 schema:value 10.1038/bjc.2016.419
177 rdf:type schema:PropertyValue
178 N89d14967743247f7a067b7be404ada26 schema:issueNumber 4
179 rdf:type schema:PublicationIssue
180 N8feda4afaf1e45d8928f39338e4bcc98 schema:name University of California, San Diego Moores Cancer Center, 3855 Health Sciences Drive, MC #0658, La Jolla, CA 92093-0658, USA
181 rdf:type schema:Organization
182 N9294eefcafc54106af639d876ed34e73 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Aged
184 rdf:type schema:DefinedTerm
185 N93e18c697bd84458971342dd3641cc72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Antineoplastic Agents
187 rdf:type schema:DefinedTerm
188 Nc4452d54077440db93719a1bc5267faf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Anilides
190 rdf:type schema:DefinedTerm
191 Nca3b4351e49247c595de44968dc50fab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Pyridines
193 rdf:type schema:DefinedTerm
194 Ncdc5a838457e42c0a68c52d457787555 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Melanoma
196 rdf:type schema:DefinedTerm
197 Nd04c1d87be1f4fb9ab91d8b66486f086 rdf:first sg:person.01106713311.45
198 rdf:rest N139689086bba436e95302a693c5766c1
199 Ne4a05816d7204435b45a98581181ccbe schema:name pubmed_id
200 schema:value 28103611
201 rdf:type schema:PropertyValue
202 Ne67d074a93f0487e81eeaeb6e773a0ae schema:volumeNumber 116
203 rdf:type schema:PublicationVolume
204 Nfffe2b0ef15d43208d2d960a01a7d460 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Proto-Oncogene Proteins c-met
206 rdf:type schema:DefinedTerm
207 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
208 schema:name Medical and Health Sciences
209 rdf:type schema:DefinedTerm
210 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
211 schema:name Oncology and Carcinogenesis
212 rdf:type schema:DefinedTerm
213 sg:journal.1017082 schema:issn 0007-0920
214 1532-1827
215 schema:name British Journal of Cancer
216 rdf:type schema:Periodical
217 sg:person.01106713311.45 schema:affiliation https://www.grid.ac/institutes/grid.266102.1
218 schema:familyName Daud
219 schema:givenName Adil
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106713311.45
221 rdf:type schema:Person
222 sg:person.01143554436.02 schema:affiliation https://www.grid.ac/institutes/grid.418628.1
223 schema:familyName Samuel
224 schema:givenName Thomas A
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01143554436.02
226 rdf:type schema:Person
227 sg:person.01150411250.57 schema:affiliation https://www.grid.ac/institutes/grid.428377.d
228 schema:familyName Schimmoller
229 schema:givenName Frauke
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150411250.57
231 rdf:type schema:Person
232 sg:person.01173210730.54 schema:affiliation https://www.grid.ac/institutes/grid.428377.d
233 schema:familyName Weitzman
234 schema:givenName Aaron L
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173210730.54
236 rdf:type schema:Person
237 sg:person.01336750727.45 schema:affiliation https://www.grid.ac/institutes/grid.47100.32
238 schema:familyName Kluger
239 schema:givenName Harriet M
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336750727.45
241 rdf:type schema:Person
242 sg:person.016216430013.43 schema:affiliation N0c3b3ba0bb4b481babbbadea2152cb33
243 schema:familyName Moussa
244 schema:givenName Ali H
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016216430013.43
246 rdf:type schema:Person
247 sg:person.0713550751.04 schema:affiliation https://www.grid.ac/institutes/grid.492843.0
248 schema:familyName Gordon
249 schema:givenName Michael S
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0713550751.04
251 rdf:type schema:Person
252 sg:person.0752005421.01 schema:affiliation https://www.grid.ac/institutes/grid.65499.37
253 schema:familyName Shapiro
254 schema:givenName Geoffrey I
255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752005421.01
256 rdf:type schema:Person
257 sg:person.0772022470.64 schema:affiliation N8feda4afaf1e45d8928f39338e4bcc98
258 schema:familyName Kurzrock
259 schema:givenName Razelle
260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772022470.64
261 rdf:type schema:Person
262 sg:pub.10.1007/s12094-011-0719-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023891155
263 https://doi.org/10.1007/s12094-011-0719-5
264 rdf:type schema:CreativeWork
265 sg:pub.10.1038/jid.2011.218 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052787397
266 https://doi.org/10.1038/jid.2011.218
267 rdf:type schema:CreativeWork
268 sg:pub.10.1038/jid.2011.421 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002802838
269 https://doi.org/10.1038/jid.2011.421
270 rdf:type schema:CreativeWork
271 sg:pub.10.1038/nature00766 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023536940
272 https://doi.org/10.1038/nature00766
273 rdf:type schema:CreativeWork
274 sg:pub.10.1038/nature10144 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050798018
275 https://doi.org/10.1038/nature10144
276 rdf:type schema:CreativeWork
277 sg:pub.10.1038/nature11183 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053677952
278 https://doi.org/10.1038/nature11183
279 rdf:type schema:CreativeWork
280 sg:pub.10.1038/ncomms6712 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025893090
281 https://doi.org/10.1038/ncomms6712
282 rdf:type schema:CreativeWork
283 sg:pub.10.1038/nrc3205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048356671
284 https://doi.org/10.1038/nrc3205
285 rdf:type schema:CreativeWork
286 sg:pub.10.1038/sj.bjc.6600919 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041973162
287 https://doi.org/10.1038/sj.bjc.6600919
288 rdf:type schema:CreativeWork
289 https://app.dimensions.ai/details/publication/pub.1076575043 schema:CreativeWork
290 https://app.dimensions.ai/details/publication/pub.1078586743 schema:CreativeWork
291 https://doi.org/10.1001/jama.2014.6096 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012801179
292 rdf:type schema:CreativeWork
293 https://doi.org/10.1002/j.1552-4604.1975.tb05919.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1052076247
294 rdf:type schema:CreativeWork
295 https://doi.org/10.1016/0895-4356(93)90163-u schema:sameAs https://app.dimensions.ai/details/publication/pub.1008750072
296 rdf:type schema:CreativeWork
297 https://doi.org/10.1016/j.canlet.2012.01.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039022477
298 rdf:type schema:CreativeWork
299 https://doi.org/10.1016/j.ccr.2009.01.021 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012366197
300 rdf:type schema:CreativeWork
301 https://doi.org/10.1016/j.ccr.2009.02.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002939839
302 rdf:type schema:CreativeWork
303 https://doi.org/10.1016/j.clindermatol.2012.08.013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027903625
304 rdf:type schema:CreativeWork
305 https://doi.org/10.1016/j.ctrv.2012.01.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024044063
306 rdf:type schema:CreativeWork
307 https://doi.org/10.1016/j.ejca.2008.12.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037621530
308 rdf:type schema:CreativeWork
309 https://doi.org/10.1016/s0140-6736(12)60868-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1003772891
310 rdf:type schema:CreativeWork
311 https://doi.org/10.1016/s0140-6736(14)60958-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012632588
312 rdf:type schema:CreativeWork
313 https://doi.org/10.1056/nejmoa1000584 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028808360
314 rdf:type schema:CreativeWork
315 https://doi.org/10.1056/nejmoa1003466 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052212829
316 rdf:type schema:CreativeWork
317 https://doi.org/10.1056/nejmoa1103782 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041864150
318 rdf:type schema:CreativeWork
319 https://doi.org/10.1056/nejmoa1112302 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051449373
320 rdf:type schema:CreativeWork
321 https://doi.org/10.1056/nejmoa1406037 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047704810
322 rdf:type schema:CreativeWork
323 https://doi.org/10.1056/nejmoa1408868 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000859328
324 rdf:type schema:CreativeWork
325 https://doi.org/10.1056/nejmoa1412082 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012352031
326 rdf:type schema:CreativeWork
327 https://doi.org/10.1056/nejmoa1504030 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024843336
328 rdf:type schema:CreativeWork
329 https://doi.org/10.1056/nejmra041245 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005930121
330 rdf:type schema:CreativeWork
331 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
332 rdf:type schema:CreativeWork
333 https://doi.org/10.1097/01.cmr.0000222598.27438.82 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003133820
334 rdf:type schema:CreativeWork
335 https://doi.org/10.1097/cmr.0000000000000242 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027998728
336 rdf:type schema:CreativeWork
337 https://doi.org/10.1097/ppo.0b013e3181bd0431 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009285554
338 rdf:type schema:CreativeWork
339 https://doi.org/10.1158/0008-5472.can-03-0245 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026966842
340 rdf:type schema:CreativeWork
341 https://doi.org/10.1158/0008-5472.can-10-0489 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012978908
342 rdf:type schema:CreativeWork
343 https://doi.org/10.1158/1078-0432.ccr-06-0776 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028934066
344 rdf:type schema:CreativeWork
345 https://doi.org/10.1158/1078-0432.ccr-10-3169 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031380951
346 rdf:type schema:CreativeWork
347 https://doi.org/10.1158/1535-7163.mct-11-0264 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025899139
348 rdf:type schema:CreativeWork
349 https://doi.org/10.1158/1538-7445.am2011-3587 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063238417
350 rdf:type schema:CreativeWork
351 https://doi.org/10.1158/2159-8290.cd-11-0240 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021811835
352 rdf:type schema:CreativeWork
353 https://doi.org/10.1200/jco.2005.03.6723 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007324791
354 rdf:type schema:CreativeWork
355 https://doi.org/10.1200/jco.2010.32.4145 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031276220
356 rdf:type schema:CreativeWork
357 https://doi.org/10.1200/jco.2011.29.15_suppl.3010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083947519
358 rdf:type schema:CreativeWork
359 https://doi.org/10.1200/jco.2012.45.0494 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013364059
360 rdf:type schema:CreativeWork
361 https://doi.org/10.1200/jco.2016.34.15_suppl.9502 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106842822
362 rdf:type schema:CreativeWork
363 https://doi.org/10.1200/jco.2016.34.15_suppl.9530 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106842850
364 rdf:type schema:CreativeWork
365 https://doi.org/10.1371/journal.pone.0010770 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004687723
366 rdf:type schema:CreativeWork
367 https://doi.org/10.1593/neo.111102 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017478734
368 rdf:type schema:CreativeWork
369 https://doi.org/10.21037/atm.2016.05.04 schema:sameAs https://app.dimensions.ai/details/publication/pub.1068831922
370 rdf:type schema:CreativeWork
371 https://www.grid.ac/institutes/grid.266102.1 schema:alternateName University of California, San Francisco
372 schema:name University of California, San Francisco Medical Center at Parnassus, 1600 Divisadero Street, MZ Bldg A, San Francisco, CA 94115, USA
373 rdf:type schema:Organization
374 https://www.grid.ac/institutes/grid.418628.1 schema:alternateName Cleveland Clinic Florida
375 schema:name Department of Hematology/Oncology, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331, USA
376 rdf:type schema:Organization
377 https://www.grid.ac/institutes/grid.428377.d schema:alternateName Exelixis (United States)
378 schema:name Exelixis Inc., 210 E. Grand Avenue, South San Francisco, CA 94080, USA
379 rdf:type schema:Organization
380 https://www.grid.ac/institutes/grid.47100.32 schema:alternateName Yale University
381 schema:name Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, PO Box 208028, New Haven, CT 06520-8028, USA
382 rdf:type schema:Organization
383 https://www.grid.ac/institutes/grid.492843.0 schema:alternateName Pinnacle Oncology Hematology
384 schema:name Pinnacle Oncology Hematology, 9055 E. Del Camino, Suite 100, Scottsdale, AZ 85258, USA
385 rdf:type schema:Organization
386 https://www.grid.ac/institutes/grid.65499.37 schema:alternateName Dana–Farber Cancer Institute
387 schema:name Department of Medical Oncology, Dana-Farber Cancer Institute, Early Drug Development Center, 450 Brookline Avenue, Boston, MA 02215, USA
388 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...